Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines
- PMID: 33065038
- PMCID: PMC7546260
- DOI: 10.1016/j.ymthe.2020.10.002
Pros and Cons of Adenovirus-Based SARS-CoV-2 Vaccines
References
-
- Kajon A.E., Lamson D.M., St George K. Emergence and re-emergence of respiratory adenoviruses in the United States. Curr. Opin. Virol. 2019;34:63–69. - PubMed
-
- Mennechet F.J.D., Paris O., Ouoba A.R., Salazar Arenas S., Sirima S.B., Takoudjou Dzomo G.R., Diarra A., Traore I.T., Kania D., Eichholz K. A review of 65 years of human adenovirus seroprevalence. Expert Rev. Vaccines. 2019;18:597–613. - PubMed
-
- Gray G.E., Moodie Z., Metch B., Gilbert P.B., Bekker L.G., Churchyard G., Nchabeleng M., Mlisana K., Laher F., Roux S., HVTN 503/Phambili study team Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study. Lancet Infect. Dis. 2014;14:388–396. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous